Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
27 results
D1.270 - Irish Infant Allergy and Nutrition: A Content Analysis of Public-Facing Online Guidance
D1.273 - Burden of food allergy on daily life and emotions in children and parents: Insights from the IPAA French Cohort
D1.274 - Evaluating adherence to and effectiveness of food allergy advice in parents of infants under 6 months old suffering from atopic dermatitis
D1.264 - A Case of Chronic Food Protein-Induced Enterocolitis Syndrome triggered by Egg Yolk via Breast Milk
D1.265 - Predicting Milk Ladder Outcomes for Management of IgE-Mediated Cow’s Milk Protein Allergy: Feature Selection Using Machine Learning Methods
D1.266 - Phenotypes of IgE-mediated Cow’s Milk Protein Allergy in an Irish Cohort Using Latent Class Analysis
D1.267 - Clinical Features and Dairy Triggers for Cow’s Milk Allergy among 342 Chinese Children in a University-affiliated Allergy Clinic in Hong Kong
D1.268 - Advancing Paediatric Egg Allergy Management via Telemedicine: Outcomes of Remote Egg Ladder Support
D1.271 - Parental Vaccine Hesitancy And Immunization Practices In Children With Food Allergy
D1.272 - Improving Culinary Medicine and Food Allergy Knowledge Through a STEM-Integrated Medical-Student-Led Cooking Program for Youth in New Orleans
D1.275 - Pollen-Food Allergy Syndrome among Final-Year Primary School Students in the City of Olsztyn and Olsztyn County, Poland: A Questionnaire-Based Cross-Sectional Study
D1.277 - Selective goat’s and sheep’s milk anaphylaxis: Advocacy for mandatory food labeling of milk origins
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download